The Publisher regrets that this article is an accidental duplication of an article that has
already been published in Journal of Cardiology, 73/6 (2018) 507–514, https://doi …

Background: Since the direct oral anticoagulants (DOAC) were introduced, oral
anticoagulant (OAC) prescription patterns have rapidly changed in patients with atrial …

Background Statins are frequently prescribed with direct oral anticoagulants (DOACs), and
previous studies have raised concerns about the increased risk of intracerebral hemorrhage …

Background The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial …

Purpose We conducted a multicenter real-world study in China to assess the association
between body mass index (BMI) and clinical outcomes in patients with atrial fibrillation (AF) …

Background: While direct oral anticoagulants (DOACs) are considered safe among patients
without chronic kidney disease (CKD), the evidence is conflicting as to whether they are also …

Background Ischemic strokes (IS) occurring in patients taking non-vitamin K antagonist oral
anticoagulants (NOACs) are becoming increasingly more frequent. We aimed to determine …

Background and Purpose—We compared the 1-year safety and effectiveness of rivaroxaban
15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with …

Background The safety and effectiveness of reduced-dose apixaban 2.5 mg twice daily (BID)
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …

We aimed to compare effectiveness and safety of the non‐vitamin K antagonist oral
anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation …